Literature DB >> 17048530

New method for the effective production of ultrafine drug nanocrystals.

Jan Möschwitzer1, Rainer H Müller.   

Abstract

Particle size reduction, particularly nanonization, is a non-specific, universal approach to improve the bioavailability of poorly soluble drugs. The decreased particle size of drug nanocrystals leads to a distinct increase in surface area. Due to the increased surface area the rate of dissolution will be proportionally raised, leading to a better absorption of the poorly soluble drug. Various technologies for the production of drug nanocrystals are known, e.g., pearl milling (Nanocrystal technology, elan/Nanosystems), high pressure homogenization in water (DissoCubes, SkyePharma) or alternatively in non-aqueous media or water-reduced media (Nanopure, PharmaSol Berlin). A first combinative technology (precipitation followed by high pressure homogenization) is known as NANOEDGETM technology (Baxter). Relatively long milling times, high numbers of homogenization cycles or solvent residues are typical drawbacks of the existing technologies. In order to overcome the limitations of the existing technologies a new combination method was developed for the production of ultra-fine submicron suspensions. The method involves an evaporation step to provide a solvent-free modified starting material followed by high pressure homogenization to produce ultrafine drug nanocrystals. In this study it could be shown that modified hydrocortisone acetate was particularly suitable to be further processed by high pressure homogenization. In comparison to jet-milled hydrocortisone acetate powder the high pressure homogenization of spray-dried hydrocortisone acetate powder resulted in much more homogeneously dispersed nanosuspensions. By using co-processed, spray-dried material (9:1 drug/poloxamer 188 ratio) the required number of homogenization cycles to obtain nanosuspensions was distinctly reduced. In case of the modified material only 1 homogenization cycle at 1500 bar was sufficient to obtain a particle size smaller than that after 20 homogenization cycles using the jet-milled drug powder. The obtained nanosuspensions have shown excellent long-term storage stability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048530     DOI: 10.1166/jnn.2006.480

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  9 in total

1.  Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.

Authors:  Sanyog Jain; Kamlesh Patel; Sumit Arora; Venkata Appa Reddy; Chander Parkash Dora
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

Review 2.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.

Authors:  Daniel Bobo; Kye J Robinson; Jiaul Islam; Kristofer J Thurecht; Simon R Corrie
Journal:  Pharm Res       Date:  2016-06-14       Impact factor: 4.200

3.  Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.

Authors:  Yue Wang; Shuhang Wang; Yingju Xu; Ping Wang; Sukai Li; Lu Liu; Mengyan Liu; Xiangqun Jin
Journal:  Int J Nanomedicine       Date:  2020-10-08

4.  Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy.

Authors:  Hans de Waard; Thomas De Beer; Wouter L J Hinrichs; Chris Vervaet; Jean-Paul Remon; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-07-13       Impact factor: 4.009

5.  Neuroprotective effects of a nanocrystal formulation of sPLA(2) inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils.

Authors:  Qun Wang; Albert Y Sun; Jana Pardeike; Rainer H Müller; Agnes Simonyi; Grace Y Sun
Journal:  Brain Res       Date:  2009-06-13       Impact factor: 3.252

Review 6.  Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics.

Authors:  Young Hee Choi; Hyo-Kyung Han
Journal:  J Pharm Investig       Date:  2017-11-28

7.  Smartcrystals for Efficient Dissolution of Poorly Water-Soluble Meloxicam.

Authors:  Rita Ambrus; Areen Alshweiat; Piroska Szabó-Révész; Csilla Bartos; Ildikó Csóka
Journal:  Pharmaceutics       Date:  2022-01-21       Impact factor: 6.321

Review 8.  Combinative Particle Size Reduction Technologies for the Production of Drug Nanocrystals.

Authors:  Jaime Salazar; Rainer H Müller; Jan P Möschwitzer
Journal:  J Pharm (Cairo)       Date:  2014-01-06

Review 9.  The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs.

Authors:  Dmitry Chistyakov; Gleb Sergeev
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.